BC Extra | Jul 19, 2019
Preclinical News

July 19 Preclinical Quick Takes: Samumed's Alzheimer's candidate; plus a CRISPR RNA editing tool, new targets for fibrosis and pain

Samumed's Alzheimer's candidate reduces tau pathology, inflammation  Samumed LLC (San Diego, Calif.) reported in an Aging Cell paper that SM07883 reduced tau phosphorylation, pathological tau aggregates, neuroinflammation, weight loss and mortality in a mouse model...
BC Extra | Apr 17, 2019
Preclinical News

Atomwise unveils Chagas disease compounds from AIMS program

Atomwise has revealed the first hit identifications by two of its AIMS program collaborators, including compounds against an unexploited target for Chagas disease, for which there are few therapies. On Tuesday, Atomwise Inc. (San Francisco,...
BC Innovations | Jun 6, 2018
Distillery Therapeutics

Infectious disease

INDICATION: Trypanosome Mouse studies identified a macrocyclic Trypanosoma rhodesain inhibitor that could help treat African trypanosomiasis. Screening of a library of cysteine protease inhibitors, in vitro activity and parasite culture assays, and structure-based optimization of...
BioCentury | Nov 29, 2017
Emerging Company Profile

Gluten-free gut

PvP Biologics Inc. is developing an oral enzyme therapy for celiac disease to break down gluten in the stomach with more specificity than a competing enzyme cocktail. The company’s KumaMax, a synthetic peptidase, should prevent...
BC Innovations | Sep 14, 2017
Translation in Brief

New Therapeutic Targets and Biomarkers: August 2017

New Therapeutic Targets and Biomarkers: August 2017 Select top therapeutic targets and biomarkers covered by BioCentury or added to the BCIQ database during August 2017. Therapeutic targets are defined as any protein, gene or other...
BC Innovations | Aug 16, 2017
Distillery Therapeutics

Infectious disease

INDICATION: Trypanosome In vitro studies identified a vinyl ketone peptide-based inhibitor of Trypanosoma rhodesain , a cysteine protease from T. brucei rhodesiense , that could help treat African trypanosomiasis. Chemical synthesis and in vitro testing of peptide-based...
BC Week In Review | Apr 4, 2016
Company News

Alvine, Immunogenics deal

Immunogenics’ ImmunogenX subsidiary acquired Alvine’s non-cash assets, including latiglutenase and three celiac disease patient-reported outcome tools. Latiglutenase is a combination of a cysteine protease (EP-B2) and a proline-specific prolyl endopeptidase (PEP) engineered to degrade gluten...
BC Innovations | Oct 15, 2015
Distillery Therapeutics

Therapeutics: Clostridium difficile toxin B (TcdB)

Infectious disease INDICATION: Clostridium In vitro and mouse studies suggest ebselen could be repurposed to treat Clostridium difficile infection (CDI). Screening of a small molecule library in an assay for binding to the cysteine protease...
BC Week In Review | Nov 4, 2013
Clinical News

ALV003: Phase IIb started

Alvine began the double-blind, placebo-controlled, dose-ranging, international Phase IIb CeliAction Study to evaluate oral ALV003 for 12 weeks in about 500 patients with celiac disease who are symptomatic despite attempting to follow a gluten-free diet....
BioCentury | Oct 7, 2013

Room for improvement

AbbVie Inc. has struck two deals for compounds that would compete with marketed products against the same targets, banking that partners Ablynx N.V. and Galapagos N.V. will be able to show their compounds produce better...
Items per page:
1 - 10 of 59